Depomed launches shingles drug
MENLO PARK, Calif. — Depomed has launched a new drug for treating shingles, the drug maker said Monday.
The company announced the launch of Gralise (gabapentin) tablets, a once-daily treatment for postherpetic neuralgia, the pain that follows healing of the rash associated with shingles.
Gralise is a proprietary formulation of gabapentin that uses patented polymer technology that enables gradual release of the drug. Depomed said it is not interchangeable with other branded or generic gabapentin-based drugs.
AJC honors L’Oréal CEO Jean-Paul Agon
NEW YORK — L’Oréal chairman and CEO Jean-Paul Agon has been honored by AJC, a global Jewish advocacy organization, with its International Human Relations Award in recognition of Agon’s "global leadership, vision and corporate citizenship."
"I believe that AJC and L’Oréal have much in common," Agon said. "We share similar core values. Ethics, integrity, respect, spirit of tolerance [and] acceptance of diversity, are as much a part of [AJC’s] DNA as it is part of [L’Oréal’s]. They resonate with the humanistic approach that will always inspire our vision and our actions as citizens of the world."
More than 600 people, including guests who traveled from France and Israel especially for the event, were in attendance during the awards dinner earlier this month at the New York Hilton. The event raised more than $1.35 million for AJC.
"We are delighted to honor Jean-Paul Agon, an outstanding corporate leader, and look forward to further strengthening our friendship and cooperation with L’Oréal," stated AJC executive director David Harris. "L’Oréal’s engagement with Israel stands out as a model for global corporations that recognize the intrinsic value of investing in and working with the Israeli people."
FDA approves Boehringer Ingelheim COPD treatment
RIDGEFIELD, Conn. — The Food and Drug Administration has approved a new product for chronic obstructive pulmonary disease made by Boehringer Ingelheim Pharmaceuticals, the drug maker said.
The company announced the approval of Combivent Respimat (ipratropium bromide and albuterol sulfate), delivered in a propellant-free inhaler that uses a slow-moving mist to deliver the same active ingredients as the Combivent Inhalation Aerosol. The new product is expected to become available in mid 2012, BI said.
"Combivent Respimat is a testament to our company’s dedication and focus on making meaningful developments in respiratory medicine," Boehringer Ingelheim Pharmaceuticals president and CEO Greg Behar said. "Leveraging our extensive respiratory therapeutic experience and a long history of bringing innovative medicines to patents, we continue to expand our strong clinical program examining the potential of several late-stage investigational compounds also delivered by the Respimat inhaler."